• Neal Gordon, Ph.D.
• Edward Machuga
• Jeffrey Radding, Ph.D.
• Kellie Watson, Ph.D.

Dr. Gordon is a veteran of over 17 years in the biotechnology industry serving both in product development and as a senior executive. From 1998 to 2004, Dr. Gordon was at Antigenics Inc, first as Vice President of Process Development and then as Senior Vice President of Manufacturing Operations. Dr. Gordon joined Antigenics in 1998, following 10 years at PerSeptive Biosystems, now part of the Applied Biosystems Group of Applera Corporation. As part of the founding technology team, he led the development, application and market launch of innovative technologies for the purification and analysis of proteins, including the BIOCAD perfusion chromatography workstation. Earlier he was a product development engineer at Proctor & Gamble. Dr. Gordon obtained a Bachelors Degree in chemical engineering from McGill University, and a Ph.D. in biochemical engineering from Massachusetts Institute of Technology.

Mr. Machuga comes to Epitome from GE Healthcare’s Research Sciences group where he served as Regional Sales Director. A seasoned sales executive with more than 20 years of experience in the life science research market, Mr. Machuga has established a strong track record building world class sales organizations. Prior to GE, Mr. Machuga served pivotal roles as VP Sales and Marketing and VP Sales at TekCel and Argonaut Technologies, leading the establishment and growth of direct sales efforts for these organizations through early commercial development. He contributed in a range of senior sales and sales management roles during his tenure at PerSeptive Biosystems/PE Biosystems, now part of the Applied Biosystems group of Applera Corporation. Mr. Machuga obtained his Bachelors degree in Biochemistry from The University of Connecticut.

Dr. Radding brings over 15 years of experience in drug development across a wide range of diseases and therapeutic targets. Prior to Epitome, at Eli Lilly, Dr. Radding spearheaded initiatives for quantitative analysis of signal transduction pathways that incorporated state-of-the-art proteomics platforms, including innovative mass spectrometry approaches. Dr. Radding obtained his Ph.D. in chemistry from Indiana University and completed post-doctoral training in the Department of Internal Medicine at Yale University School of Medicine.

Dr. Watson was a co-founder of Beacon BioPartners, LLC, a strategic and business development consultancy for biotechnology/Life Sciences companies. Prior to Beacon, she was Director of Business Development for Pyrosequencing AB, a biotechnology company that developed, manufactured and sold genetic analysis instrumentation and consumable products for the Life Sciences market. Dr. Watson was Vice President at Feinstein Kean Healthcare (an Ogilvy Public Relations subsidiary), a communications and business consultancy that specialized in scientific communications, and assisting biotechnology companies with corporate strategy to support financing and partnering activities. Dr. Watson was a postdoctoral fellow at Harvard University, where her research focused protein biochemistry and molecular genetic approaches to interrogate signal transduction pathways important in cancer. She has a Ph.D. from the University of California, Irvine, a M.S. degree from Kansas State University and a B.Sc. Honours degree from Queens University.

• Neal Gordon, Ph.D.
• Edwin Kania
• Daniel Wang, Ph.D.
• Harry Wilcox III

Dr. Gordon is a veteran of over 17 years in the biotechnology industry serving both in product development and as a senior executive. From 1998 to 2004, Dr. Gordon was at Antigenics Inc, first as Vice President of Process Development and then as Senior Vice President of Manufacturing Operations. Dr. Gordon joined Antigenics in 1998, following 10 years at PerSeptive Biosystems, now part of the Applied Biosystems Group of Applera Corporation. As part of the founding technology team, he led the development, application and market launch of innovative technologies for the purification and analysis of proteins, including the BIOCAD perfusion chromatography workstation. Earlier he was a product development engineer at Proctor & Gamble. Dr. Gordon obtained a Bachelors Degree in chemical engineering from McGill University, and a Ph.D. in biochemical engineering from Massachusetts Institute of Technology.

Mr. Kania is Managing Partner and Chairman of Flagship Ventures. Prior to co-founding Flagship Ventures in 1999, he spent 15 years as Managing General Partner of OneLiberty Ventures and as General Partner at its predecessor firm, Morgan Holland Ventures. His direct investment experience covers over 100 companies. In addition, he has been intimately involved in the launch and development of more than a dozen companies as the founding and lead investor. Mr. Kania is currently a director of Aspect Medical Systems (NASDAQ: ASPM), EXACT Sciences (NASDAQ: EXAS), Abla-Tx, Acceleron Pharma, Interactive Supercomputing Corporation, Nanostream, Inc., and Pervasis Therapeutics. Mr. Kania also serves as Chairman of the Board of TransMedics and VisEn Medical. He is also a director of the Massachusetts Biotechnology Council. Mr. Kania holds a degree in physics from Dartmouth College and an MBA from the Harvard Business School.

Dr. Wang is Institute Professor of Chemical Engineering at the Massachusetts Institute of Technology. Dr. Wang is an expert and world leader in protein research. Dr. Wang's current work as Institute Professor of Chemical Engineering includes research into the production of recombinant proteins, glycoprotein quality and protein stabilization. He has numerous publications and awards, including the 1995 Amgen Biochemical Engineering Award. Dr. Wang is a member of the National Academy of Engineering and American Academy of Arts and Sciences. Dr. Wang earned his Ph.D. at the University of Pennsylvania, and his SM and SB degree at MIT.

Mr. Wilcox is a Partner and Chief Financial Officer of Flagship Ventures. His career spans 28 years and has involved many different roles and functions including Controller, CFO, Sr. VP BD, and CEO. He has served on several Boards of Directors. In addition to his corporate experience, Mr. Wilcox was previously CFO of two venture capital firms, Highland Capital Partners where he was the founding CFO and General Partner, and prior to that, Charles River Ventures. Most recently, he served as CFO and Sr. VP Corporate Development for EXACT Sciences. In addition to his role at EXACT Sciences, Mr. Wilcox led an active consulting practice which included roles as interim CEO of two biotech companies: Thrasos Therapeutics and Biostratum. Prior to this, Mr. Wilcox was Executive Vice President, Chief of Finance and Corporate Development of Pyrosequencing, a publicly-held biotech company. Earlier, he had been the President and Chief Executive Officer of Cambridge NeuroScience, Inc. until its sale to CeNeS Pharmaceuticals, and before that Sr. VP Business Development and CFO of Cellcor.

• Ruedi Aebersold, Ph.D.
• Noubar Afeyan, Ph.D.
• James Collins, Ph.D.
• Joseph Davie, M.D., Ph.D.
• Richard DiMarchi, Ph.D.
• Sam Hanash, M.D., Ph.D.
• Thomas Joos, Ph.D.
• Douglas Lauffenburger, Ph.D.
• Forest White, Ph.D.

Dr. Ruedi Aebersold, one of the pioneers in the field of proteomics, is known for developing a series of methods that have found wide application in analytical protein chemistry and proteomics. He developed a method for the rapid identification and accurate quantification of cellular proteins, i.e. for the generation of cellular "protein profiles," based on a new class of reagents (Isotope Coded Affinity Tags or ICAT reagents), and mass spectrometry. The "protein profiles" are used to differentiate cells, such as noncancerous vs. cancerous cells, and to systematically study how cells respond to external stimuli. This may lead to new diagnostic markers for disease and to a more complete understanding of the biochemical processes involved in cell physiology. Dr. Aebersold's mass spectrometry work has earned him several prestigious awards:

• 2002 Biemann Medal, from the American Society of Mass Spectrometry, recognizes significant achievement in basic or applied mass spectrometry early in an individual's career.
• 2002 Michael Widmer Award, from the Novartis Pharma and the Analytical Division of the Swiss Chemical Society at the HPLC 2002 Congress in Montreal, honors Aebersold's extraordinary and innovative contributions in analytical protein biochemistry and proteomics.
• 2002 Individual World Technology Award for Biotechnology recognizes innovative individuals who are contributing to the advance of emerging technologies for the benefit of business and society and who will likely become or remain key players in the technological drama unfolding in coming years.

Dr. Aebersold is full professor at the Institute of Biotechnology at the Swiss Federal Institute of Technology (ETH) in Zurich and his research group is part of the newly founded Institute of Molecular Systems Biology. Dr. Aebersold earned his Ph.D. in Cellular Biology at the University of Basel in 1983 and served on the faculties of the Universities of Washington and British Columbia, until 2000, when he co-founded the Institute for Systems Biology with Drs. Leroy Hood and Alan Aderem. Dr. Aebersold serves on the SAB of a number of academic and private sector research organizations and is on several editorial boards in the fields of protein science, genomics, and proteomics.

Dr. Afeyan is a recognized technologist and entrepreneur, having founded and helped build several successful technology startups during the past 17 years. Dr. Afeyan is a Senior Lecturer at MIT's Sloan School of Management and is a frequent guest speaker at technology forums throughout the country. He has authored numerous scientific publications and patents. Dr. Afeyan earned his undergraduate degree in Chemical Engineering from McGill University and his Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology. Prior to co-founding Flagship Ventures in 1999, Dr. Afeyan helped launch six highly successful new ventures. He was the Founder, Chairman, and CEO of PerSeptive Biosystems (formerly Nasdaq: PBIO), a leader in the bio-instrumentation field. Dr. Afeyan also served as Chairman of the Board of ChemGenics Pharmaceuticals, a privately held company spun out of PerSeptive. After PerSeptive's acquisition by Applera Corporation (NYSE: ABI), Dr. Afeyan was Applera's Senior Vice President and Chief Business Officer. While at Applera, he initiated and oversaw the creation of Celera Genomics (NYSE: CRA), a tracking stock subsidiary of Applera. Dr. Afeyan has also been a founding team member, investor and active board member/advisor of Antigenics (Nasdaq: AGEN), Color Kinetics and EXACT Sciences (Nasdaq: EXAS). Dr. Afeyan currently serves as a Director for Flagship portfolio companies Affinnova, Beyond Genomics, Compound Therapeutics, Ensemble Discovery, Genstruct and Helicos BioSciences. He is a member of the Board of Governors of Boston University Medical School, and several advisory boards including, the Whitehead Institute at MIT, the McGowan Institute for Regenerative Medicine at the University of Pittsburgh, the Center for Bits and Atoms at MIT's Media Lab, and the Faculty of Engineering at McGill University. He is also a Board member of several economic development organizations aimed at rebuilding the former Soviet Republic of Armenia.

Dr. Collins is a University Professor, Professor of Biomedical Engineering, and Co-Director of the Center for BioDynamics at Boston University. He received a doctorate in medical engineering from the University of Oxford in 1990. Dr. Collins is one of the founders of the emerging field of synthetic biology, and a pioneering research in systems biology. His honors include a Rhodes Scholarship, a MacArthur "genius award", an NIH Director's Pioneer Award, an Ellison Medical Foundation Senior Scholar Award in Aging, and being selected for the inaugural Technology Review TR100 (top young innovators) and the Scientific American 50 (top outstanding leaders in science and technology). Dr. Collins is a Fellow of the American Physical Society, the Institute of Physics and the American Institute for Medical and Biological Engineering.

Dr. Davie joins Epitome Biosystems™ after holding positions as Senior Vice President, Department of Research at Biogen, Inc. and Corporate Senior Vice President, Science and Technology, at G.D. Searle & Co. Before entering the corporate world, Dr. Davie was Head of the Department of Microbiology and Immunology at Washington University School of Medicine, St. Louis, Missouri. Dr. Davie received his Ph.D. in bacteriology from Indiana University and his M.D. from Washington University School of Medicine.

Dr. DiMarchi is the Linda & Jack Gill Chair in Biomolecular Sciences and Professor of Chemistry at Indiana University. He is a retired Group Vice President at Eli Lilly & Company where for more than two decades he provided leadership for biotechnology, endocrine research and product development. He currently serves as a co-founder and board member of the biotechnology companies Ambrx, and Inproteo. He previously served as a board member of the biotechnology trade group BIO, and Millennium Biotherapeutics. Dr. DiMarchi’s current scientific activities remain focused on the relationship of protein structure and function, with a particular interest in novel methods of macromolecular synthesis and drug delivery. He contributed appreciably to the discovery of Humalog® and commercial development of Humulin®, Humatrope®, Glucagon®, Xigris®, Forteo®, and Evista®. Humalog represents the first biosynthetic hormone optimized by rDNA technology approved as a human medicine and presently registers annual sales in excess of one billon US dollars. He is a leading proponent for the integration of new technologies and approaches to pharmaceutical R&D and an ardent proponent of molecular diversity. Dr. DiMarchi received his Ph.D. in Biochemistry from Indiana University.

Dr. Hanash’s interests and expertise focus on developing and applying integrated approaches to the molecular profiling of cancer, with emphasis on proteomics. Dr. Hanash’s Ph.D. is in Human Genetics with clinical training in Pediatric Oncology. He has been a program principal investigator (PI) for multi-investigator projects funded by the National Cancer Institute (NCI) while at the University of Michigan, including program projects and most recently, PI for an NCI-funded Director’s Challenge program, focused on molecular profiling of lung, colon and ovarian cancers and PI of a NCI-funded Cancer Biomarker Development program, focused on the applying proteomics to the discovery of protein markers for early diagnosis of lung and GI cancers. Dr. Hanash has organized and participated in several workshops sponsored by the NCI related to cancer diagnostics and molecular profiling. Dr. Hanash relocated from the University of Michigan to the Fred Hutchinson Cancer Research Center (August 1, 2004) to lead a newly developed program in Molecular Diagnostics. Dr. Hanash will serve as program director for this project and will supervise all project personnel. Dr. Hanash is the former and first President of HuPO, the Human Proteome Organization. This prestigious international society will help set the research agenda in proteomics for years to come. Dr. Hanash earned his M.D. from the American University of Beirut and his Ph.D. in human genetics from University of Michigan.

Dr. Joos is head of the Biochemistry Department of the NMI Natural and Medical Sciences Institute at the University of Tübingen. Dr. Joos is a scientific advisor of BioChipNet (www.biochionet.de), a member of the editorial board of Drug Discovery Today, Proteomics, Molecular Biotechnology and Expert Review of Proteomics. He is a member of the scientific advisory board of the "National Centre of Human Proteomics" at the Royal College of Surgeons, Dublin, Ireland and the "Plasma Proteome Institute" Washington, DC, USA. Dr. Joos is an invited speaker, advisor and chairman at major international biochip conferences. He has published numerous papers, including recent articles in Drug Discovery Today, Proteomics, and Trends in Biotechnology. Dr. Joos is a world leading expert and opinion leader within the field of protein microarray technology. Dr. Joos earned his Ph.D. in biochemistry from the University of Tubingen.

Dr. Lauffenburger is the Director of the Biological Engineering Division and Uncas & Helen Whitaker Professor of Biological Engineering, Chemical Engineering and Biology at the Massachusetts Institute of Technology (MIT). He is also a Member of the Center for Cancer Research, Center for Biomedical Engineering, and Biotechnology Process Engineering Center at MIT. He serves as Director on the Executive Committee of the MIT Computational & Systems Biology Initiative. Dr. Lauffenburger is presently on the Board of Directors of Genstruct and has served as a consultant and/or scientific advisory board member for Astra-Zeneca, CellPro, Entelos, Insert Therapeutics, Johnson & Johnson, Pfizer, SyStemix, the Burroughs-Wellcome Foundation, and the Whitaker Foundation. Dr. Lauffenburger earned his Ph.D. in chemical engineering from the University of Minnesota.

Dr. White is an Assistant professor in the Biological Engineering Division at the Massachusetts Institute of Technology (MIT). His research is focused on quantitative analysis of cellular signaling networks on a proteome-wide scale with site specific resolution. After receiving his Ph.D. from Florida State University in 1997, he was a post-doctoral associate in Don Hunt’s lab at the University of Virginia from 1997-1999, where he developed an improved method for affinity capture of phosphorylated peptides. After completion of his post-doc, Dr. White joined MDS Proteomics as a Senior Research Scientist with the task of further developing protein phosphorylation analysis methodology (phosphoproteomics). In July, 2003, he joined the Division of Biological Engineering at MIT as an Assistant Professor and has recently been named as a Mitsui Career Development Professor.